» Articles » PMID: 10221851

Effects of Hormonal Contraceptives on Bone Mineral Density

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 1999 Apr 30
PMID 10221851
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical research to date on the effects of 3 types of hormonal contraceptives, i.e. depot medroxyprogesterone acetate ('Depo-Provera'), levonorgestrel subdermal implants ('Norplant'), and oral contraceptives, on bone mineral density in premenopausal women is reviewed. The large variance in results across studies for each method is in part due to differences in research design, techniques for measuring bone mineral density, age of the study participants and type of oral contraceptive preparation. However, the balance of the evidence leans toward a positive effect of oral contraceptives on bone mineral density in women of all age. On the other hand, few observations have yet been published on the effects of the new progestin oral contraceptives on bone mineral density. The few extant data suggest a positive impact of levonorgestrel subdermal implants on bone mineral density in women of all ages. Although the findings are preliminary, it appears that depot medroxyprogesterone acetate may exert a negative effect on bone mineral density. More specifically, caution should be exercised in prescribing long term depot medroxyprogesterone acetate (e.g. > 5 years) especially in young adolescents (e.g. < 16 years old) who may not have yet reached peak bone mass.

Citing Articles

Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.

Kasonde M, Niska R, Rose C, Henderson F, Segolodi T, Turner K PLoS One. 2014; 9(3):e90111.

PMID: 24625530 PMC: 3953113. DOI: 10.1371/journal.pone.0090111.


Osteoporosis in a young woman after 6 years of levonorgestrel administration from intrauterine devices?.

Greiner C, Brune K, Haen E BMJ Case Rep. 2011; 2009.

PMID: 21686786 PMC: 3030178. DOI: 10.1136/bcr.07.2008.0484.


Bone mineral density in young adult survivors of acute lymphoblastic leukemia.

Thomas I, Donohue J, Ness K, Dengel D, Baker K, Gurney J Cancer. 2008; 113(11):3248-56.

PMID: 18932250 PMC: 2597561. DOI: 10.1002/cncr.23912.


Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.

Sivin I Drug Saf. 2003; 26(5):303-35.

PMID: 12650633 DOI: 10.2165/00002018-200326050-00002.

References
1.
Dhuper S, Warren M, Brooks-Gunn J, Fox R . Effects of hormonal status on bone density in adolescent girls. J Clin Endocrinol Metab. 1990; 71(5):1083-8. DOI: 10.1210/jcem-71-5-1083. View

2.
Kleerekoper M, Brienza R, Schultz L, Johnson C . Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med. 1991; 151(10):1971-6. View

3.
Kritz-Silverstein D, Barrett-Connor E . Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health. 1993; 83(1):100-2. PMC: 1694525. DOI: 10.2105/ajph.83.1.100. View

4.
Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K . Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception. 1997; 56(1):1-3. DOI: 10.1016/s0010-7824(97)00066-8. View

5.
Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, SIZONENKO P . Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab. 1992; 75(4):1060-5. DOI: 10.1210/jcem.75.4.1400871. View